Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China

Liang Zhao,Hongyao Du,Mahin Alamgir,Jing Yang,Xiao-ping Miao,Biling Jiang,Yuting Xia,Y. Lou,Yujue Wang,Chen Shen,Jinjin Zhu,W. Chung,Yan Li,J. Tao
DOI: https://doi.org/10.1684/ejd.2020.3908
2020-11-01
Abstract:EJD, vol. 30, n◦ 6, November-December 2020 [7, 8]. This is very important because these patients can unknowingly infect other persons and contribute to the spread of the infection: their isolation is therefore necessary [8]. Further studies are required to establish whether urticaria involves mainly the limbs (as in our patients and those reported by other authors [7, 10]), itching is mild [5, 10] (also in one of our patients) and whether it is possible that urticaria, as a first clinical manifestation, occurs in patients with COVID-19 of mild to moderate severity [5, 8].
Medicine
What problem does this paper attempt to address?